CUE
insider transactionsCue Biopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
+136.4K
136.4K buy · 0 sell
Net value · 30d
$1000.0K
$1000.0K in · $0 out
Sentiment · 30d
Net buying
100% buying · 0% selling
Open-market trades · 30d
2
136.4K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Shao-Lee Lin KEY
Chief Executive Officer
—
45.5K sh
Own New
-
Buy·P
Shao-Lee Lin KEY
Chief Executive Officer
$1000.0K
90.9K sh · $11.00
Own New
-
Grant·A
Director
$0
1.6K sh
Own New
-
Grant·A
Director
$0
1.6K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Shao-Lee Lin KEY | Buy P | 45.5K | — |
| Jun 1, 2026 | Shao-Lee Lin KEY | Buy P | 90.9K | $1000.0K |
| May 30, 2026 | Viola Mong Meehan | Grant A | 1.6K | $0 |
| May 30, 2026 | Daniel A. Camardo | Grant A | 1.6K | $0 |
About CUE insider trading
This page tracks insider transactions for Cue Biopharma, Inc. (CUE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.